Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryNov272012	Fate Therapeutics Initiates Phase 2 Clinical Study of ProHema for the Treatment of Hematologic Malignancies Fate Therapeutics Initiates Phase 2 Clinical Study of ProHema for the Treatment of Hematologic Malignancies San Diego, CA – Fate Therapeutics, Inc. , a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, announced today the initiation of a Read All »	View HTML Fate Therapeutics Initiates Phase 2 Clinical Study of ProHema for the Treatment of Hematologic Malignancies 12 KB
Toggle SummarySep182017	Fate Therapeutics Initiates Phase 2 PROTECT Study of ProTmune™ for Prevention of Acute Graft-versus-Host Disease Independent Data Monitoring Committee Conducts Phase 1 Safety Review and Unanimously Recommends Opening of Phase 2 Enrollment First Seven Subjects Receiving ProTmune Clear Phase 1 Safety Objectives of Engraftment and Survival at Day 28 Phase 1 Day 100 Acute GvHD Data Expected to be Presented at Read All »	View HTML Fate Therapeutics Initiates Phase 2 PROTECT Study of ProTmune™ for Prevention of Acute Graft-versus-Host Disease 19.4 KB
Toggle SummaryFeb262010	Fate Therapeutics Named One of the 50 Most Innovative Companies in the World By MIT's Technology Review San Diego, CA – Fate Therapeutics, Inc. announced today that the Company was named as one of Technology Review’s 2010 TR50 , the first annual list of the 50 most innovative companies in the world. The 2010 TR50 companies span the fields of energy, computing, the Web, biomedicine, and Read All »	View HTML Fate Therapeutics Named One of the 50 Most Innovative Companies in the World By MIT’s Technology Review 11.9 KB
Toggle SummaryFeb282014	Fate Therapeutics Observes Rare Disease Day 2014 SAN DIEGO, Feb. 28, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, is joining the Muscular Dystrophy Association (MDA) and other advocacy organizations Read All »	View HTML Fate Therapeutics Observes Rare Disease Day 2014 14.2 KB
Toggle SummaryApr222013	Fate Therapeutics Presents Efficacy Data for WNT7a-Analog Program at Muscular Dystrophy Association 2013 Scientific Conference San Diego, CA – Fate Therapeutics, Inc., a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, announced today the presentation of preclinical data from its WNT7a protein analog program for the treatment of muscular dystrophy at the Read All »	View HTML Fate Therapeutics Presents Efficacy Data for WNT7a-Analog Program at Muscular Dystrophy Association 2013 Scientific Conference 14 KB
Toggle SummaryDec102019	Fate Therapeutics Presents its First Off-the-shelf, iPSC-derived CAR T-Cell Cancer Immunotherapy Program at ASH Annual Meeting FT819 Exhibits Enhanced Tumor Clearance In Vivo Compared to Primary CAR T Cells in Preclinical Leukemia Model Master Engineered iPSC Line for FT819 Fully Characterized for Complete Elimination of TCR Expression and Integration of Novel 1XX CAR into TRAC Locus with No Evidence of Off-target Effects Read All »	View HTML
Toggle SummaryApr012019	Fate Therapeutics Presents Late-Breaking Preclinical Data Highlighting Unique Advantages of Clonal Master Engineered iPSC Lines for Off-the-Shelf CAR T-cell Therapy at 2019 AACR Annual Meeting High-Throughput Selection of a Single Gene-Edited iPSC Enables Mass Production of Uniformly Engineered CAR T Cells FT819 Off-the-Shelf CAR19 T-cell Product Candidate Demonstrates Complete Elimination of TCR Expression and Integration of Novel 1XX CAR into TRAC Locus SAN DIEGO, Calif. Read All »	View HTML
Toggle SummaryDec042018	Fate Therapeutics Presents Off-the-Shelf CAR T and NK Cell Cancer Immunotherapy Pipeline at ASH Annual Meeting FT500, First-ever iPSC-derived Cell Product Candidate Cleared for U.S. Clinical Investigation by FDA, Featured in Oral Presentation SAN DIEGO , Dec. 04, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of Read All »	View HTML
Toggle SummaryDec062020	Fate Therapeutics Presents Patient Case Study Demonstrating Clinical Activity of FT596 in Refractory Diffuse Large B-cell Lymphoma Off-the-Shelf, iPSC-derived CAR NK Cell Product Candidate Drives Partial Response at First Dose Level of 30 Million Cells Deepening of Response Observed with FT596 Retreatment Duration of Response Comparable to FDA-approved Autologous CAR T-cell Therapy for Patients with Partial Response No Read All »	View HTML
Toggle SummaryDec072015	Fate Therapeutics Provides Update on Adoptive Immunotherapy Programs for Hematopoietic Cell Transplantation Supportive Interim Data from ProHema® PUMA Study Demonstrate the Therapeutic Potential of Programmed Donor Cells Clinical Development Strategy to Focus on Prevention of Life-Threatening Complications in Mobilized Peripheral Blood HCT ProTmune™ to Advance into Phase 1/2 Clinical Trial for Read All »	View HTML Fate Therapeutics Provides Update on Adoptive Immunotherapy Programs for Hematopoietic Cell Transplantation 27.5 KB

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.